The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIQE Regulatory News (IQE)

Share Price Information for IQE (IQE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 34.00
Bid: 33.90
Ask: 34.25
Change: 0.00 (0.00%)
Spread: 0.35 (1.032%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 34.00
IQE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update and comment on US Entity List

24 May 2019 07:00



Trading Update and comment on US Entity List

IQE plc

Cardiff, UK. 24th May 2019: IQE plc (AIM: IQE; "IQE", the “Company” or the "Group"), the leading global supplier of advanced wafer products and materials solutions to the semiconductor industry, provides the following trading update in response to action taken by the Bureau of Industry and Security (BIS) of the United States Department of Commerce to add Huawei Technologies Co., Ltd. and 68 of its affiliates (“Huawei”) to the “Entity List” maintained by the Department. The BIS action prohibits the sale to Huawei, by certain of IQE’s customers, of products covered by the Export Administration Regulations (EAR) absent obtaining an appropriate export license.

IQE wishes to clarify its potential exposure to this rapidly evolving situation, as it supplies epitaxial wafers to multiple chip companies in global supply chains, some of whom supply Huawei.

The situation involving the ban is dynamic and it is not clear at this time how long it will remain in force or what the full implications will be. However, IQE believes it is in a strong position to adjust to the possible consequences and scenarios resulting from this in a positive manner. Across all product lines, IQE has supply relationships with multiple non-US customers, so is well placed to adapt to mid to long-term share shifts at both the component (chip) and the OEM level. The majority of IQE’s technologies and supply chains are not affected by the ban and IQE complies fully with the EAR.

In the short-term, IQE believes it may experience some delay to orders and the potential for adjustment of supplier managed inventory levels, predominantly in its Wireless Business Unit. The Photonics and Infrared Business Units are essentially unaffected.

The company has been engaging across its customer base in recent days specifically on this subject and estimates that its current maximum risk exposure to this matter is less than 5% of total FY 2019 revenue guidance.

Although there remains uncertainty and unpredictability related to this specific matter, given the market opportunity IQE faces in H2, the company leaves full year guidance unchanged.

Dr Drew Nelson, Chief Executive of IQE, said:

‘The recent ban on sales of products from US companies to Huawei and its affiliates is a factor completely outside of IQE’s control. However, our long-term strategy of supplying as many of the supply chains into all major OEMs as possible, protects IQEs overall supply to a very significant degree. As a result, we believe the ban will have a limited impact on our mid to long term revenue trajectory. Indeed, the breadth of IQE’s current product range, the new materials technologies being introduced to market over the coming months and years, and IQE’s global manufacturing footprint are powerful mitigating factors in dealing effectively with the ongoing changing geopolitical landscape in our industry."

The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

CONTACTS:

  
  
  

IQE plc +44 (0) 29 2083 9400Tim PullenDrew NelsonChris Meadows Canaccord Genuity (Nomad and Joint Broker) + 44 (0) 20 7523 8000Simon BridgesRichard Andrews

Peel Hunt (Joint Broker) +44 (0) 20 7418 8900Edward KnightNick Prowting

ABOUT IQE

http://iqep.com IQE is the leading global supplier of advanced semiconductor wafers that enable a diverse range of applications, supported by an innovative outsourced foundry services portfolio that allows the Group to provide a 'one stop shop' for the wafer needs of the world's leading semiconductor manufacturers. IQE uses advanced crystal growth technology (epitaxy) to manufacture and supply bespoke semiconductor wafers 'epi-wafers' to the major chip manufacturing companies, who then use these wafers to make the chips which form the key components of virtually all high technology systems. IQE is unique in being able to supply wafers using all of the leading crystal growth technology platforms. IQE's products are found in many leading-edge consumer, communication, computing and industrial applications, including a complete range of wafer products for the wireless industry, such as smartphones and wireless infrastructure, Wi-Fi, base stations, and satellite communications; optical communications, optical storage, printing, thermal imagers, leading-edge medical technologies, automotive and aerospace technologies, a variety of advanced silicon based systems and high efficiency concentrator photovoltaic (CPV) solar cells. IQE is headquartered in Cardiff UK and operates multiple manufacturing and R&D facilities worldwide.


Date   Source Headline
22nd Aug 20137:00 amRNSIQE reports new CPV cell efficiency
5th Jun 20132:22 pmRNSMerger Update
8th Mar 20133:00 pmRNSMerger Update
8th Jan 20138:39 amRNSStatement regarding press articles
31st Jul 20123:54 pmRNSDirectorate Change
10th Apr 20125:11 pmRNSDirector Dealings
27th Mar 20122:00 pmRNSPartnership Agreement
8th Feb 20124:10 pmRNSCompletion of Placing
17th Feb 20103:56 pmRNSNominated Adviser Change of Name
7th Aug 20094:42 pmRNSHolding(s) in Company
7th Aug 20094:30 pmRNSBondholders meeting
7th Aug 20093:51 pmRNSDirector Dealing in Shares
12th Jun 20081:42 pmRNSAdditional Listing
15th Apr 20087:01 amRNSAdditional Listing
7th Apr 200812:14 pmRNSDirector/PDMR Shareholding
28th Mar 200811:52 amRNSDirector/PDMR Shareholding
19th Mar 20087:00 amRNSDirector/PDMR Shareholding
17th Mar 20081:00 pmRNSContract Win
17th Mar 20087:01 amRNSFinal Results
28th Feb 20083:27 pmRNSHolding(s) in Company
19th Feb 20088:30 amRNSNotice of Results
25th Jan 20087:00 amRNSBank Facilities
17th Jan 20087:00 amRNSTrading Update
16th Jan 200811:15 amRNSBroker Appointment
15th Jan 200812:12 pmRNSDirector/PDMR Shareholding
9th Jan 20084:26 pmRNSAdditional Listing
7th Jan 20087:00 amRNSDirector/PDMR Shareholding
4th Jan 200812:46 pmRNSHolding(s) in Company
19th Dec 20077:30 amRNSAdditional Listing
18th Dec 20073:52 pmRNSSubstrate supply contract
13th Dec 20077:01 amRNSSuccessful Qualifications
9th Nov 200710:53 amRNSDirector/PDMR Shareholding
3rd Oct 200710:41 amRNSDirector/PDMR Shareholding
1st Oct 20072:44 pmRNSAdditional Listing
28th Sep 200710:14 amRNSContract Win
28th Sep 20078:12 amRNSInvestor Presentation
4th Sep 200712:03 pmRNSDirector/PDMR Shareholding
28th Aug 20072:17 pmRNSHolding(s) in Company
24th Aug 20073:36 pmRNSHolding(s) in Company
22nd Aug 20077:01 amRNSContract Win
22nd Aug 20077:01 amRNSInterim Results
15th Aug 20077:01 amRNSIFRS Transitional Stmnt - Amd
14th Aug 20077:01 amRNSIFRS Transitional Statement
13th Aug 20071:19 pmRNSRule 26 Compliance
2nd Aug 20078:39 amRNSResearch Consortium
1st Aug 20073:52 pmRNSNotice of Results
25th Jul 20071:35 pmRNSResult of AGM
11th Jul 20078:00 amRNSHolding(s) in Company
9th Jul 20077:00 amRNSTrading Statement
18th Jun 20073:35 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.